Visit the link to Onclive for Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the treatment landscape in newly diagnosed metastatic colorectal cancer (mCRC).

There are many therapeutic options for patients with mCRC, although the majority have retained their chemotherapeutic backbone, says Eng. It is important to keep that in mind, as many patients express interest in pursuing immunotherapy. Patients who are eligible for this approach account for less than 5% of the total mCRC population, she adds.

In terms of standard regimens, physicians can use FOLFOX or FOLFIRI. However, if a patient has a good performance status and their laboratory tests are within normal limits, Eng advises a more aggressive approach with FOLFOXIRI.

Source: Onclive

Pin It on Pinterest